
We provide superior efficiency and speed for new drug discovery.
This involves comprehensive systems for exploring and identifying target diseases and technology that can assist in the highly sensitive analysis and evaluation and initial screening during the exploration stages of candidate compounds in the drug development process.
We offer non-GLP discovery bioanalytical services either in support of studies conducted in-house or as a stand-alone service, which can adapt to meet the rapid timelines and diverse needs required for the most efficient lead candidate selection.
Discovery PK study
Customization of methods for your own samples
Investigation & Development of Ultrasensitive assay(quantitative sensitivity level of pg-fg/mL)
Tuning of equipment and development of sample preparation method
Overall technology concerning LC-MS/MS
LC-MS/MS
Ultra-Sensitive Analysis; API 5000
Quantitative analysis; Metabolite profiling and identification; 4000Q-Trap
Quantitative analysis; Amino-acid analysis; 2000Q-Trap
Robots
Solid-phase extraction, Automatic pipetting device; Micro LAB STAR
Enzyme reaction, amino-acid derivatization; AP-2
Advanced Medical Science Research Center
Gene Expression Profiling
Genome Mutation Analyses
Drug Efficacy Parameters and Development of Measurement Methods
Measurement of Drug Concentrations in Protein Preparations
Cytokine Analysis in Peripheral Blood
Protein Expression Profiling by Two-Dimensional Electrophoresis
in vitro Phospholipidosis Screening
in vitro Hepatotoxicity Screening
Photocytotoxicity Tests
Others
Genotoxicity Studies
in vitro tests
in vivo tests All of our research and studies are in strict adherence to the laws concerning protection and management of animals with full respect of the standards concerning care and management of test animals, and have been accepted and certified for animal welfare practices.